These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 25475413

  • 1. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
    Di Marzo V, Centonze D.
    CNS Neurosci Ther; 2015 Mar; 21(3):215-21. PubMed ID: 25475413
    [Abstract] [Full Text] [Related]

  • 2. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG, Henze T, Essner U, Trompke C, Vila Silván C.
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [Abstract] [Full Text] [Related]

  • 3. Multiple sclerosis symptoms and spasticity management: new data.
    Izquierdo G.
    Neurodegener Dis Manag; 2017 Nov; 7(6s):7-11. PubMed ID: 29143581
    [Abstract] [Full Text] [Related]

  • 4. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Paolicelli D, Direnzo V, Manni A, D'Onghia M, Tortorella C, Zoccolella S, Di Lecce V, Iaffaldano A, Trojano M.
    J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
    [Abstract] [Full Text] [Related]

  • 5. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J.
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [Abstract] [Full Text] [Related]

  • 6. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG, Vila C.
    Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
    [Abstract] [Full Text] [Related]

  • 7. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R.
    Clin Neuropharmacol; 2018 May; 41(5):171-176. PubMed ID: 30024443
    [Abstract] [Full Text] [Related]

  • 8. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
    Marková J.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):9-13. PubMed ID: 30657024
    [Abstract] [Full Text] [Related]

  • 9. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.
    Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C.
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [Abstract] [Full Text] [Related]

  • 10. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
    Patti F.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S.
    J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
    Ziemssen T.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):1-2. PubMed ID: 30657019
    [Abstract] [Full Text] [Related]

  • 15. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J, Feneberg W, Meier M, Pöllmann W.
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [Abstract] [Full Text] [Related]

  • 16. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O.
    Eur Neurol; 2014 Sep; 72 Suppl 1():9-11. PubMed ID: 25278117
    [Abstract] [Full Text] [Related]

  • 17. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    Patti F.
    Eur Neurol; 2016 Sep; 75 Suppl 1():9-12. PubMed ID: 26901344
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P, Trojano M.
    Eur Neurol; 2016 Sep; 76(5-6):216-226. PubMed ID: 27732980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.